Synthesis and biological assessment of novel β-lactamase inhibitors in the framework of tuberculosis therapy in India

Tuberculosis (TB) is an infectious disease responsible for 220.000 deaths per year in India, imposing an immense burden on the country’s health care system. This project aims at establishing an innovative approach in anti-TB therapy by designing β-lactamase inhibitors that could allow classical
β-lactam antibiotics to exert their antibacterial action against (resistant) Mycobacterium tuberculosis strains.